Pulmonary mucormycosis (2011 study) Skip to main content
Review Semin Respir Crit Care Med 2011

Pulmonary mucormycosis

Hamilos G, Samonis G, Kontoyiannis D, Semin Respir Crit Care Med, 2011

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

The authors wrote a review of pulmonary mucormycosis, a serious fungal lung infection, covering who gets it, why it is hard to treat, and which treatments offer the best chance of survival.

What They Found

This review describes mucormycosis as a life-threatening opportunistic fungal infection that affects people with weakened immune defences, including those with severe neutropenia, those taking corticosteroids or other immunosuppressive medicines, those with poorly controlled diabetes, and those with iron overload. It has recently appeared as a breakthrough sinopulmonary infection in blood cancer patients and transplant recipients who were taking antifungal prophylaxis that does not work against Mucorales. Unlike pulmonary aspergillosis, the outlook for pulmonary mucormycosis has not improved much over the last decade, mainly because early diagnosis is difficult and current antifungal drugs have limited activity against Mucorales. The authors state that prompt lipid amphotericin B-based antifungal therapy, reversal of underlying host factors, and an aggressive surgical approach offer the best chances for survival.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

This is a narrative review rather than a trial, so the abstract reports no new patient data, and it does not describe how the literature was selected or compare treatments directly.

This plain-language summary was generated with AI assistance from the study's abstract; it has not been individually reviewed by a clinician. Always consult the source study and a qualified healthcare professional. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Review
Category Infection
Source Pubmed
PubMed ID 22167397
Year Published 2011
Journal Semin Respir Crit Care Med
MeSH Terms Antifungal Agents; Debridement; Humans; Hyperbaric Oxygenation; Immunocompromised Host; Lung Diseases, Fungal; Mucor; Mucorales; Mucormycosis; Opportunistic Infections; Rhizomucor; Rhizopus

Cite This Study

Share

Find a Canadian Clinic

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last updated: March 19, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology